title: Cardiomyopathy in neurological disorders.
abstract: According to the American Heart Association, cardiomyopathies are classified as primary (solely or predominantly confined to heart muscle), secondary (those showing pathological myocardial involvement as part of a neuromuscular disorder) and those in which cardiomyopathy is the first/predominant manifestation of a neuromuscular disorder. Cardiomyopathies may be further classified as hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, or unclassified cardiomyopathy (noncompaction, Takotsubo-cardiomyopathy). This review focuses on secondary cardiomyopathies and those in which cardiomyopathy is the predominant manifestation of a myopathy. Any of them may cause neurological disease, and any of them may be a manifestation of a neurological disorder. Neurological disease most frequently caused by cardiomyopathies is ischemic stroke, followed by transitory ischemic attack, syncope, or vertigo. Neurological disease, which most frequently manifests with cardiomyopathies are the neuromuscular disorders. Most commonly associated with cardiomyopathies are muscular dystrophies, myofibrillar myopathies, congenital myopathies and metabolic myopathies. Management of neurological disease caused by cardiomyopathies is not at variance from the same neurological disorders due to other causes. Management of secondary cardiomyopathies is not different from that of cardiomyopathies due to other causes either. Patients with neuromuscular disorders require early cardiologic investigations and close follow-ups, patients with cardiomyopathies require neurological investigation and avoidance of muscle toxic medication if a neuromuscular disorder is diagnosed. Which patients with cardiomyopathy profit most from primary stroke prevention is unsolved and requires further investigations.
authors: Krankenanstalt Rudolfstiftung, Vienna, Austria. Electronic address: fifigs1@yahoo.de.
authors: Josef
authors: J
authors: Finsterer
authors: Claudia
authors: C
authors: Stöllberger
authors: Karim
authors: K
authors: Wahbi
mesh_terms: D009202:Cardiomyopathies / Q000145:classification / Q000150:complications* / Q000473:pathology; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009422:Nervous System Diseases / Q000150:complications* / Q000473:pathology; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control
chemical_list: D002316:Cardiotonic Agents
keywords: Arrhythmias; Cardiomyopathy; Dilation; Embolism; Genetics; Myocardial thickening; Myopathy; Neuromuscular disorders; Restrictive filling pattern; Stroke